Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study
- 1 August 2002
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 360 (9334), 671-677
- https://doi.org/10.1016/s0140-6736(02)09836-7
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Ep-CAM LEVELS IN PROSTATIC ADENOCARCINOMA AND PROSTATIC INTRAEPITHELIAL NEOPLASIAJournal of Urology, 1999
- Estimates of the worldwide mortality from 25 cancers in 1990International Journal of Cancer, 1999
- Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target?Journal of Clinical Pathology, 1999
- Detection of Surface Antigen 17-1A in Breast and Colorectal CancerHybridoma, 1999
- Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1ACancer Immunology, Immunotherapy, 1996
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancerThe Lancet, 1995
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final ReportAnnals of Internal Medicine, 1995
- Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinomaThe Lancet, 1994
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodiesInternational Journal of Cancer, 1986